ORG Wealth Partners LLC Buys 8,417 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

ORG Wealth Partners LLC boosted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 85.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,240 shares of the company’s stock after purchasing an additional 8,417 shares during the quarter. ORG Wealth Partners LLC’s holdings in Roivant Sciences were worth $216,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Gladius Capital Management LP acquired a new stake in shares of Roivant Sciences during the third quarter worth about $35,000. Point72 Hong Kong Ltd acquired a new stake in Roivant Sciences during the 2nd quarter valued at approximately $36,000. US Bancorp DE boosted its holdings in shares of Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after acquiring an additional 1,948 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after acquiring an additional 1,288 shares during the period. Finally, Quarry LP purchased a new position in shares of Roivant Sciences during the second quarter worth $53,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on ROIV shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Roivant Sciences has an average rating of “Moderate Buy” and a consensus price target of $17.93.

Insider Activity at Roivant Sciences

In related news, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total value of $1,132,000.00. Following the completion of the transaction, the chief operating officer now directly owns 606,525 shares in the company, valued at approximately $6,865,863. This represents a 14.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CIO Mayukh Sukhatme sold 185,946 shares of Roivant Sciences stock in a transaction on Tuesday, December 24th. The shares were sold at an average price of $12.00, for a total value of $2,231,352.00. Following the completion of the sale, the executive now owns 18,836,547 shares in the company, valued at $226,038,564. This represents a 0.98 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,942,629 shares of company stock valued at $23,071,486. 7.90% of the stock is owned by insiders.

Roivant Sciences Price Performance

ROIV stock traded down $0.29 during mid-day trading on Friday, reaching $10.73. 2,405,537 shares of the company’s stock were exchanged, compared to its average volume of 4,142,402. The company has a market cap of $7.81 billion, a price-to-earnings ratio of 1.90 and a beta of 1.27. Roivant Sciences Ltd. has a 12-month low of $9.69 and a 12-month high of $13.06. The stock’s 50 day moving average is $11.88 and its 200 day moving average is $11.58.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.